Stryker’s $1.43 billion settlement for defective hip implants stands as one of the largest medical device settlements in U.S. history, compensating thousands of patients who experienced catastrophic implant failures. Announced on November 3, 2014, the settlement resolved claims for patients who received the Rejuvenate or ABG II hip stem devices—modular designs that shed metallic debris as components rubbed against each other, causing tissue damage, bone loss, and requiring emergency revision surgery. The settlement offered affected plaintiffs an average of approximately $300,000 each, making it one of the more substantial per-person payouts in orthopedic device litigation. The implant failures weren’t isolated incidents.
Patients who thought they had successful hip replacements often returned to the operating room years later with loosening implants, elevated metal ions in their blood, and significant pain. A 51-year-old woman from Ohio received a Rejuvenate implant in 2009 expecting it to last 15 years or more. By 2013, she experienced severe hip pain, imaging showed the implant was failing, and blood tests revealed cobalt and chromium levels five times higher than normal. She required revision surgery, months of recovery, and permanently lost work income during her most productive earning years. Her experience typified what thousands of other Rejuvenate and ABG II recipients endured—a cascade of failures that cost far more than the implants themselves.
Table of Contents
- What Were the Stryker Hip Implants That Failed?
- How Much Did Stryker Pay and Who Qualified for the Settlement?
- What Medical Problems Did These Implants Cause?
- How Did Litigation Lead to the Settlement?
- What Happened to Patients Who Missed the Claim Deadline?
- What Litigation Continues Today?
- What Can Current and Former Hip Replacement Patients Learn from the Stryker Situation?
- Conclusion
What Were the Stryker Hip Implants That Failed?
The Rejuvenate and ABG II hip stems were modular-neck implants, a design concept that seemed appealing in theory but proved problematic in practice. The modular neck allowed surgeons to adjust the angle and length of the implant to better match individual patient anatomy. However, the connection point between the neck and stem became a site of corrosion and crevice corrosion, where metallic particles—primarily cobalt, chromium, and molybdenum—would shed into surrounding tissue. Stryker received warnings about these issues as early as 2008, yet the devices remained on the market until the company issued a recall in July 2012. Stryker sold hundreds of thousands of these implants before the recall.
The devices were marketed as advanced solutions for hip replacement, and many patients had no reason to suspect they were receiving defective hardware. Surgeons relied on Stryker’s marketing and safety assurances. By the time the recall came, many patients were already experiencing symptoms—loosening, pain, elevated metal ion levels—while others would experience failures years later. The modular design that promised better patient outcomes instead created a ticking time bomb of implant failures across the patient population. A separate settlement also addressed the LFIT Anatomic CoCR V40 femoral head, which settled confidentially in November 2018 under proceedings in Massachusetts and New Jersey. While less widely publicized than the Rejuvenate settlement, this agreement acknowledged additional hip implant defects and expanded recognition of Stryker’s liability across multiple product lines.
How Much Did Stryker Pay and Who Qualified for the Settlement?
The $1.43 billion settlement created a claims process for eligible patients who had received revision surgery for their failed Stryker implants before November 3, 2014. The acceptance rate was remarkably high—95% of eligible claimants agreed to the settlement terms, indicating both the legitimacy of the claims and the quality of legal representation for the plaintiffs’ bar. This high acceptance rate reflected the strength of the evidence: documented implant failures, medical records showing metal ion elevation, and the clear causal link between the defective design and the need for additional surgery. The compensation structure attempted to account for the real harms patients experienced. Beyond the average $300,000 per plaintiff figure, settlements recognized that individual damages varied significantly.
Compensation covered medical expenses including the revision surgery itself, lost wages during recovery and rehabilitation, pain and suffering, and in some cases, future medical expenses for ongoing orthopedic care. A 62-year-old patient from Michigan who required two revision surgeries received a substantially higher settlement than a younger patient requiring only one additional procedure. However, the settlement process also had limitations—claims had to be filed by March 2, 2015, and patients who couldn’t document their implant or revision surgery faced difficulty establishing eligibility, even if they had clear evidence of device failure. The settlement was split across 39 states, meaning it was structured as a multistate agreement rather than a single class action. This approach had practical implications: some claimants faced different proof requirements or slightly different timelines depending on their state, adding complexity to an already difficult claims process.
What Medical Problems Did These Implants Cause?
Patients with Rejuvenate and ABG II implants reported consistent patterns of failure. The most common symptoms included progressive hip pain, audible clicking or popping in the joint, reduced mobility, and imaging findings showing implant loosening. Laboratory blood tests frequently revealed elevated cobalt and chromium levels—indicators of metal debris shedding from the implant. These elevated metal ions raised additional health concerns beyond the immediate implant failure. Some patients developed a condition called pseudotumor, where a ball of inflammatory tissue formed around the implant in response to the metallic particles and corrosion byproducts. A 58-year-old man from Pennsylvania received a Rejuvenate implant in 2009. Six years later, he presented with severe groin pain and imaging showed a large pseudotumor—a mass of scar tissue and fluid that occupied the space where healthy muscle had been.
Surgeons had to remove the implant, excise the pseudotumor tissue, and perform extensive soft tissue reconstruction. His recovery took months, and he developed permanent hip weakness from the tissue damage. The implant had not simply failed in the mechanical sense; it had actively harmed the surrounding anatomy through corrosion byproducts. Another documented risk was accelerated bone loss around the implant. As the implant loosened and metal particles accumulated, bone resorption accelerated, making revision surgery more complex. Surgeons often had to use bone grafts to rebuild bone structure, turning a standard revision into a more complicated reconstructive procedure. Patients who delayed seeking treatment for early symptoms often had worse outcomes because their bone loss progressed further.
How Did Litigation Lead to the Settlement?
The path to the $1.43 billion settlement involved coordinated litigation across multiple jurisdictions. Cases were consolidated into multidistrict litigation (MDL 2441) in Minnesota, where they could be more efficiently managed. Stryker faced mounting legal pressure as plaintiffs’ lawyers documented the scope of implant failures, obtained internal company communications showing prior knowledge of defects, and calculated the cumulative damages across thousands of affected patients. The company faced the prospect of individual jury trials across the country, each with the potential for substantial verdicts and bad publicity.
Rather than fight multiple trials, Stryker agreed to negotiate a global settlement that would resolve all pending cases and prevent future litigation over the Rejuvenate and ABG II devices. This approach reflected a calculated decision: settling was cheaper and more predictable than the risk of multiple jury trials. For plaintiffs’ counsel, the settlement offered certainty and compensation for their clients without the years of additional litigation that individual trials would require. However, the settlement was also time-limited—the March 2, 2015 deadline meant that patients who weren’t aware of the recall or didn’t pursue claims by that date were essentially barred from the settlement process.
What Happened to Patients Who Missed the Claim Deadline?
One significant limitation of the Stryker settlement was its strict claim deadline of March 2, 2015. For patients whose implant failures manifested after that date or who simply weren’t aware of the settlement opportunity, the deadline created a barrier to recovery. A patient in Florida whose Rejuvenate implant failed in 2016 missed the settlement window entirely, despite having documented implant failure and revision surgery. Her legal options were severely limited because the settlement had closed and new claims against Stryker for the same products became much harder to pursue. This scenario highlights a critical downside of structured mass settlements: they resolve cases efficiently but can exclude late-manifesting injuries or claims. Patients didn’t always know their implant was defective immediately.
Some experienced gradual loosening over years before symptoms became severe enough to seek medical attention. Others were unaware that a settlement opportunity existed. Once the deadline passed, these patients had limited recourse. Some pursued individual lawsuits, but without the class action framework and settlement fund, they faced higher litigation costs and uncertain outcomes. Stryker’s insurance carriers and the company itself benefited from the deadline because it created a finality to liability. After March 2, 2015, Stryker could assert that the settled claims issue was resolved, which protected the company’s balance sheet and allowed it to move forward commercially.
What Litigation Continues Today?
As of April 2026, litigation surrounding Stryker hip implants continues on multiple fronts. MDL 2441 in Minnesota, presided by Senior Judge Donovan W. Frank, remains open and addresses ongoing claims related to Rejuvenate and ABG II defects. Additionally, MDL 2768 in Massachusetts addresses the LFIT Anatomic CoCR V40 femoral head defects, with 55 pending cases as of April 2026.
Both MDLs continue to receive new case transfers from state courts, indicating that implant failures are still being identified and patients are still seeking legal recourse. Law firms continue actively accepting new cases for patients with documented Stryker implant failures. This ongoing litigation reflects several realities: some patients didn’t receive the recalled implants until after the recall was issued, some implants are failing years later in unexpected ways, and some patients are pursuing claims outside the settled framework for other reasons. The litigation environment is active but fragmented—patients file cases individually or in state courts, and those cases may be transferred to federal MDLs where they participate in ongoing coordination with other claimants.
What Can Current and Former Hip Replacement Patients Learn from the Stryker Situation?
The Stryker hip implant case offers important lessons for patients considering hip replacement or already living with implants. First, implants aren’t permanent solutions—revision surgery is a realistic possibility that patients should discuss with their surgeons before receiving an implant. Second, maintaining relationships with orthopedic specialists and obtaining periodic imaging can identify problems early when revision surgery is less complex. Third, patients should stay informed about recall notices and safety warnings from the FDA and their implant manufacturers, rather than assuming silence means safety.
For patients still living with Stryker implants today, the situation has stabilized somewhat since the 2014 recall and subsequent settlement. Stryker’s remaining products have been redesigned with improved materials and connections. However, patients with older implants—particularly those from 2009 to 2012—should remain vigilant for symptoms of failure and maintain regular communication with their orthopedic surgeon. The history of the Rejuvenate and ABG II devices demonstrates that even widely marketed products from major manufacturers can have serious defects that weren’t obvious until large populations had received the implants.
Conclusion
The Stryker hip implant settlement represents a significant but incomplete resolution to a major orthopedic device failure. The $1.43 billion settlement provided meaningful compensation to 95% of eligible patients who experienced Rejuvenate and ABG II implant failures, with average awards of approximately $300,000 recognizing both the medical costs and human toll of failed implants. However, the settlement also had limits—patients who missed the March 2, 2015 deadline or whose implants failed in unexpected ways remained outside the structured resolution, and ongoing litigation continues to address subsequent failures and related products like the LFIT Anatomic femoral head.
If you received a Stryker hip implant and experienced revision surgery for implant failure, you may have qualified for the original settlement if you filed by the deadline. If you’re currently living with a Stryker implant, maintain regular contact with your orthopedic surgeon and monitor for symptoms of failure. If your implant has recently failed or you’re experiencing metal ion-related complications, consult with an orthopedic surgeon immediately and consider whether your situation may be addressed through ongoing litigation in MDL 2441 or MDL 2768, or through state-level lawsuits where legal claims may still be viable.